vs
Beam Therapeutics Inc.（BEAM）与Planet Labs PBC（PL）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是Planet Labs PBC的1.4倍（$114.1M vs $81.3M），Beam Therapeutics Inc.净利率更高（214.1% vs -72.8%，领先286.9%），Beam Therapeutics Inc.同比增速更快（279.5% vs 32.6%），Planet Labs PBC自由现金流更多（$1.9M vs $-87.0M）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
Planet Labs PBC（常简称为Planet）是总部位于美国加利福尼亚州旧金山的上市地球影像企业，核心目标是实现全球范围的每日成像，以此监测地表变化、精准识别相关趋势，为多行业的地理数据分析需求提供可靠的数据支持。
BEAM vs PL — 直观对比
营收规模更大
BEAM
是对方的1.4倍
$81.3M
营收增速更快
BEAM
高出246.9%
32.6%
净利率更高
BEAM
高出286.9%
-72.8%
自由现金流更多
PL
多$88.9M
$-87.0M
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $81.3M |
| 净利润 | $244.3M | $-59.2M |
| 毛利率 | — | 57.3% |
| 营业利润率 | -15.3% | -22.6% |
| 净利率 | 214.1% | -72.8% |
| 营收同比 | 279.5% | 32.6% |
| 净利润同比 | 370.4% | -194.7% |
| 每股收益（稀释后） | $2.53 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMPL
| Q4 25 | $114.1M | $81.3M | ||
| Q3 25 | — | $73.4M | ||
| Q2 25 | — | $66.3M | ||
| Q1 25 | — | $61.6M | ||
| Q4 24 | — | $61.3M | ||
| Q3 24 | — | $61.1M | ||
| Q2 24 | — | $60.4M | ||
| Q1 24 | — | $58.9M |
净利润BEAMPL
| Q4 25 | $244.3M | $-59.2M | ||
| Q3 25 | — | $-22.6M | ||
| Q2 25 | — | $-12.6M | ||
| Q1 25 | — | $-35.2M | ||
| Q4 24 | — | $-20.1M | ||
| Q3 24 | — | $-38.7M | ||
| Q2 24 | — | $-29.3M | ||
| Q1 24 | — | $-30.1M |
毛利率BEAMPL
| Q4 25 | — | 57.3% | ||
| Q3 25 | — | 57.6% | ||
| Q2 25 | — | 55.2% | ||
| Q1 25 | — | 62.1% | ||
| Q4 24 | — | 61.2% | ||
| Q3 24 | — | 52.9% | ||
| Q2 24 | — | 52.4% | ||
| Q1 24 | — | 55.2% |
营业利润率BEAMPL
| Q4 25 | -15.3% | -22.6% | ||
| Q3 25 | — | -24.5% | ||
| Q2 25 | — | -34.4% | ||
| Q1 25 | — | -31.5% | ||
| Q4 24 | — | -36.9% | ||
| Q3 24 | — | -64.8% | ||
| Q2 24 | — | -57.2% | ||
| Q1 24 | — | -57.6% |
净利率BEAMPL
| Q4 25 | 214.1% | -72.8% | ||
| Q3 25 | — | -30.8% | ||
| Q2 25 | — | -19.1% | ||
| Q1 25 | — | -57.1% | ||
| Q4 24 | — | -32.8% | ||
| Q3 24 | — | -63.3% | ||
| Q2 24 | — | -48.5% | ||
| Q1 24 | — | -51.1% |
每股收益（稀释后）BEAMPL
| Q4 25 | $2.53 | $-0.19 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.12 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | — | $-0.13 | ||
| Q2 24 | — | $-0.10 | ||
| Q1 24 | — | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $443.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $349.6M |
| 总资产 | $1.5B | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BEAMPL
| Q4 25 | $1.2B | $443.3M | ||
| Q3 25 | — | $181.1M | ||
| Q2 25 | — | $133.5M | ||
| Q1 25 | — | $118.0M | ||
| Q4 24 | — | $139.0M | ||
| Q3 24 | — | $148.3M | ||
| Q2 24 | — | $107.4M | ||
| Q1 24 | — | $83.9M |
股东权益BEAMPL
| Q4 25 | $1.2B | $349.6M | ||
| Q3 25 | — | $435.7M | ||
| Q2 25 | — | $444.8M | ||
| Q1 25 | — | $441.3M | ||
| Q4 24 | — | $464.6M | ||
| Q3 24 | — | $473.2M | ||
| Q2 24 | — | $500.3M | ||
| Q1 24 | — | $518.0M |
总资产BEAMPL
| Q4 25 | $1.5B | $1.1B | ||
| Q3 25 | — | $696.4M | ||
| Q2 25 | — | $658.4M | ||
| Q1 25 | — | $633.8M | ||
| Q4 24 | — | $630.8M | ||
| Q3 24 | — | $658.4M | ||
| Q2 24 | — | $674.6M | ||
| Q1 24 | — | $702.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | $28.6M |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | $1.9M |
| 自由现金流率自由现金流/营收 | -76.3% | 2.3% |
| 资本支出强度资本支出/营收 | 3.3% | 32.9% |
| 现金转化率经营现金流/净利润 | -0.34× | — |
| 过去12个月自由现金流最近4个季度 | — | $40.7M |
8季度趋势，按日历期对齐
经营现金流BEAMPL
| Q4 25 | $-83.3M | $28.6M | ||
| Q3 25 | — | $67.8M | ||
| Q2 25 | — | $17.3M | ||
| Q1 25 | — | $-6.3M | ||
| Q4 24 | — | $4.1M | ||
| Q3 24 | — | $-7.9M | ||
| Q2 24 | — | $-4.3M | ||
| Q1 24 | — | $-6.8M |
自由现金流BEAMPL
| Q4 25 | $-87.0M | $1.9M | ||
| Q3 25 | — | $47.5M | ||
| Q2 25 | — | $9.2M | ||
| Q1 25 | — | $-17.9M | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $-23.0M | ||
| Q2 24 | — | $-14.2M | ||
| Q1 24 | — | $-15.7M |
自由现金流率BEAMPL
| Q4 25 | -76.3% | 2.3% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 13.9% | ||
| Q1 25 | — | -29.1% | ||
| Q4 24 | — | -5.8% | ||
| Q3 24 | — | -37.6% | ||
| Q2 24 | — | -23.6% | ||
| Q1 24 | — | -26.7% |
资本支出强度BEAMPL
| Q4 25 | 3.3% | 32.9% | ||
| Q3 25 | — | 27.6% | ||
| Q2 25 | — | 12.3% | ||
| Q1 25 | — | 18.9% | ||
| Q4 24 | — | 12.5% | ||
| Q3 24 | — | 24.8% | ||
| Q2 24 | — | 16.4% | ||
| Q1 24 | — | 15.1% |
现金转化率BEAMPL
| Q4 25 | -0.34× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
PL
| Defense And Intelligence | $49.4M | 61% |
| Civil Government | $18.8M | 23% |
| Commercial | $13.1M | 16% |
